Development and prospects for bispecific antibody-based therapeutics in cancer and other applications

Lawrence G. Lum; Zaid Al-Kadhimi

doi:10.1517/17460441.3.9.1081

Development and prospects for bispecific antibody-based therapeutics in cancer and other applications

Lawrence G. Lum, Zaid Al-Kadhimi

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Background: Progress in molecular biology for the production of bispecific antibodies (BiAbs) and the expanding knowledge on receptors on malignant and normal target cells provide the basis for developing new strategies using antibody- and/or receptor-based platform technology for the treatment of cancer and other diseases. Objective: This review provides a preclinical and clinical perspective on application of bispecific antibodies for the treatment of solid tumors, hematologic malignancies and other diseases. Methods: This review focuses on BiAb-based immunotherapy, clinical trials, alternative strategies, the challenges of technology and future applications. Results/conclusion: The successful application of a particular BiAb will depend on a thorough evaluation of the expected functional application and thoughtful engineering of structure, affinity and number of binding sites based on the desired function.

Original language	English (US)
Pages (from-to)	1081-1097
Number of pages	17
Journal	Expert Opinion on Drug Discovery
Volume	3
Issue number	9
DOIs	https://doi.org/10.1517/17460441.3.9.1081
State	Published - Sep 2008
Externally published	Yes

Keywords

Bispecific antibodies
Fc-receptors
Immunotherapy
Monoclonal antibodies
NK cells
T cells
Targeted T cells
Tumor antigens

ASJC Scopus subject areas

Drug Discovery

Access to Document

10.1517/17460441.3.9.1081

Cite this

@article{0743f06af2014cfc832dead0e54bf352,

title = "Development and prospects for bispecific antibody-based therapeutics in cancer and other applications",

abstract = "Background: Progress in molecular biology for the production of bispecific antibodies (BiAbs) and the expanding knowledge on receptors on malignant and normal target cells provide the basis for developing new strategies using antibody- and/or receptor-based platform technology for the treatment of cancer and other diseases. Objective: This review provides a preclinical and clinical perspective on application of bispecific antibodies for the treatment of solid tumors, hematologic malignancies and other diseases. Methods: This review focuses on BiAb-based immunotherapy, clinical trials, alternative strategies, the challenges of technology and future applications. Results/conclusion: The successful application of a particular BiAb will depend on a thorough evaluation of the expected functional application and thoughtful engineering of structure, affinity and number of binding sites based on the desired function.",

keywords = "Bispecific antibodies, Fc-receptors, Immunotherapy, Monoclonal antibodies, NK cells, T cells, Targeted T cells, Tumor antigens",

author = "Lum, {Lawrence G.} and Zaid Al-Kadhimi",

note = "Funding Information: The studies by LG Lum involving activated T cells and ATC armed with BiAbs were funded in part by R01 CA 092344 and 5P30 CA022453 from the NIH, Translational Grant from the Leukemia and Lymphoma Society, Susan G. Komen Foundation Grant, Michigan Cell Therapy Center for Excellence Grant from the State of Michigan, and funding from the Barbara Ann Karmanos Cancer Institute. Z Al-Kadhimi received support from Leukemia Research Foundation #440374 and Michigan Cell Therapy Center Grant. LG Lum is the founder of Transtarget, Inc.",

year = "2008",

month = sep,

doi = "10.1517/17460441.3.9.1081",

language = "English (US)",

volume = "3",

pages = "1081--1097",

journal = "Expert Opinion on Drug Discovery",

issn = "1746-0441",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Development and prospects for bispecific antibody-based therapeutics in cancer and other applications

AU - Lum, Lawrence G.

AU - Al-Kadhimi, Zaid

N1 - Funding Information: The studies by LG Lum involving activated T cells and ATC armed with BiAbs were funded in part by R01 CA 092344 and 5P30 CA022453 from the NIH, Translational Grant from the Leukemia and Lymphoma Society, Susan G. Komen Foundation Grant, Michigan Cell Therapy Center for Excellence Grant from the State of Michigan, and funding from the Barbara Ann Karmanos Cancer Institute. Z Al-Kadhimi received support from Leukemia Research Foundation #440374 and Michigan Cell Therapy Center Grant. LG Lum is the founder of Transtarget, Inc.

PY - 2008/9

Y1 - 2008/9

N2 - Background: Progress in molecular biology for the production of bispecific antibodies (BiAbs) and the expanding knowledge on receptors on malignant and normal target cells provide the basis for developing new strategies using antibody- and/or receptor-based platform technology for the treatment of cancer and other diseases. Objective: This review provides a preclinical and clinical perspective on application of bispecific antibodies for the treatment of solid tumors, hematologic malignancies and other diseases. Methods: This review focuses on BiAb-based immunotherapy, clinical trials, alternative strategies, the challenges of technology and future applications. Results/conclusion: The successful application of a particular BiAb will depend on a thorough evaluation of the expected functional application and thoughtful engineering of structure, affinity and number of binding sites based on the desired function.

AB - Background: Progress in molecular biology for the production of bispecific antibodies (BiAbs) and the expanding knowledge on receptors on malignant and normal target cells provide the basis for developing new strategies using antibody- and/or receptor-based platform technology for the treatment of cancer and other diseases. Objective: This review provides a preclinical and clinical perspective on application of bispecific antibodies for the treatment of solid tumors, hematologic malignancies and other diseases. Methods: This review focuses on BiAb-based immunotherapy, clinical trials, alternative strategies, the challenges of technology and future applications. Results/conclusion: The successful application of a particular BiAb will depend on a thorough evaluation of the expected functional application and thoughtful engineering of structure, affinity and number of binding sites based on the desired function.

KW - Bispecific antibodies

KW - Fc-receptors

KW - Immunotherapy

KW - Monoclonal antibodies

KW - NK cells

KW - T cells

KW - Targeted T cells

KW - Tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=52649138547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649138547&partnerID=8YFLogxK

U2 - 10.1517/17460441.3.9.1081

DO - 10.1517/17460441.3.9.1081

M3 - Review article

C2 - 23506181

AN - SCOPUS:52649138547

SN - 1746-0441

VL - 3

SP - 1081

EP - 1097

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

IS - 9

ER -

Development and prospects for bispecific antibody-based therapeutics in cancer and other applications

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this